分析我国柑橘研究领域近10 a(年)的热点与前沿主题,便于相关研究者了解本领域的研究现状。以Web of Science数据库中2010—2019年我国柑橘研究相关学术论文为研究对象,运用文献计量可视化软件CiteSpace对其进行作者、机构、主题词共现...分析我国柑橘研究领域近10 a(年)的热点与前沿主题,便于相关研究者了解本领域的研究现状。以Web of Science数据库中2010—2019年我国柑橘研究相关学术论文为研究对象,运用文献计量可视化软件CiteSpace对其进行作者、机构、主题词共现和文献共被引分析。检索范围内发表的我国柑橘研究论文共3 168篇,发文数量整体呈现逐年增长的趋势,受到多学科、多领域的广泛关注。研究机构以华中农业大学发文量最多,其次是西南大学、浙江大学。已经形成了以邓秀新和吴强盛等为核心的学术团队群。近10 a研究热点有组学研究、抗氧化、系统发育分析、黄龙病、丛枝菌根、柑橘精油、果实品质等。2016—2019年高突现主题词预示着当前研究热点指向柑橘有效成分及其药用价值研究。研究前沿主题涵盖柑橘黄龙病、柑橘系统发育分析、柑橘有效成分及其功能研究、丛枝菌根、柑橘果实品质研究等多个方面。其中与柑橘系统发育分析相关的文献影响力最强。近年来我国科研人员对柑橘从多学科、多领域开展了广泛、深入的研究。从研究内容来看,基础理论研究较多,与柑橘产业结合紧密的研究相对较少,有待进一步加强基础研究成果向应用领域的延伸。展开更多
BACKGROUND Colon cancer represents a significant malignant neoplasm within the digestive system,characterized by a high incidence rate and substantial disease burden.The F-box protein 22(FBXO22)plays a role in forming...BACKGROUND Colon cancer represents a significant malignant neoplasm within the digestive system,characterized by a high incidence rate and substantial disease burden.The F-box protein 22(FBXO22)plays a role in forming a specific type of ubiquitin ligase subunit,which is expressed abnormally in various malignant neoplasms and shows a notable relationship with prognosis in patients with cancer.Never-theless,the function of FBXO22 in the context of colon cancer remains inade-quately elucidated.AIM To explore the role of FBXO22 in colon cancer by examining FBXO22 expression patterns and analyzing how the protein affects the prognosis in patients who have undergone surgery.METHODS Samples of cancerous and nearby normal tissues from patients with colon cancer were gathered,along with pertinent clinical data.Expression levels of the FBXO22 gene in both cancerous and paracancerous tissues were assessed through immu-nohistochemistry.The median H score served as a criterion for categorizing FBXO22 gene expression into high and low levels in cancerous tissues,and the relationship between these expression levels and various pathologic character-istics of patients,such as age,sex,and clinical stage,was analyzed.Colon cancer cell lines HCT116 and DLD-1 were used and divided into three groups:A blank control group,a negative control group,and a si-FBXO22 group.FBXO22 gene mRNA and protein expression were measured 24 hours post-transfection using real-time fluorescence quantitative polymerase chain reaction and western blotting.The proliferation capabilities of the cells in each group were assessed using the Cell Counting Kit-8 assay and 5-ethynyl-2’-deoxyuridine assay,while cellular migration and invasion abilities were evaluated using scratch healing and Transwell assays.Various online platforms,including the Timer Immune Estimation Resource,were used to analyze pan-cancer expression,promoter methylation levels,and mutation frequencies of the FBXO22 gene in colon cancer patients.Additionally,the correlation between FBXO22 gene expression,patient prognosis,immune cell infiltration,and the expression of immune molecules in the colon cancer microenvironment was investigated.The relationship between FBXO22 gene expression and chemotherapy resistance,along with the potential mechanisms of action of the FBXO22 gene,were analyzed using The Cancer Genome Atlas dataset and the Genomics of Drug Sensitivity in Cancer drug training set via R software.RESULTS Compared with normal colonic tissues,the FBXO22 gene was highly expressed in colon cancer tissues.Post-operative patients with colon cancer elevated FBXO22 reduced survival and exhibited resistance to various chemotherapeutic agents.FBXO22 expression suppresses the infiltration of anti-tumor immune cells.In vitro,FBXO22 knockdown inhibited the proliferation and migration of colon cancer cells.CONCLUSION The FBXO22 gene is a biomarker of poor prognosis in patients with colon cancer and has potential as a target for immunotherapy and overcoming chemotherapy resistance.展开更多
Objective This study aimed to compare the upgrade rate and cancer detection rate between the 18F-DCFPyL PET/MRI-guided ultrasound fusion targeted biopsy(TB)and systematic biopsy in selected patients with suspected pro...Objective This study aimed to compare the upgrade rate and cancer detection rate between the 18F-DCFPyL PET/MRI-guided ultrasound fusion targeted biopsy(TB)and systematic biopsy in selected patients with suspected prostate cancer(the molecular imaging prostate-specific membrane antigen score of≥2 and multiparametric MRI Prostate Imaging Reporting and Data System score of≥4).Methods Eighty-seven selected biopsy-naive patients were randomized into two groups:TB(n=41)and systematic biopsy(control;n=46).Patients diagnosed with clinically significant prostate cancer proceeded to radical prostatectomy.The primary outcome was the pathological upgrade rate.Secondary outcomes,including the cancer detection rate,incidence of repeat biopsy,positive surgical margin,complications,and prostate-specific antigen level at 6 weeks postoperatively,were compared between the groups using the Pearson or Fisher's exact test,as appropriate.Results In the study,prostate cancer was ultimately detected in all patients.The TB group successfully identified all tumors,whereas five patients in the control group initially missed diagnosis.The pathological upgrade rates for the TB and control groups were 31.7%and 56.5%,respectively.Overall,the detection rate for clinically significant prostate cancer(the International Society of Urological Pathology grade of≥2)was significantly higher in the TB group(92.7%)compared with the control group(76.1%,p=0.035).However,no significant difference was found in the detection rate of all prostate cancer.Complications(Clavien–Dindo grade of≤2)occurred in both the TB group(n=11)and control group(n=13).No statistically significant difference was observed between the groups in terms of the positive surgical margin,complications,or 6-week postoperative prostate-specific antigen level.Conclusion The 18F-DCFPyL PET/MRI-guided ultrasound fusion TB alone was an efficient modality in diagnosing selected patients with prostate cancer.展开更多
基金The study was reviewed and approved by institutional ethics board of Affiliated Hospital of Hebei Engineering University(No.:2024[K]005-01).
文摘BACKGROUND Colon cancer represents a significant malignant neoplasm within the digestive system,characterized by a high incidence rate and substantial disease burden.The F-box protein 22(FBXO22)plays a role in forming a specific type of ubiquitin ligase subunit,which is expressed abnormally in various malignant neoplasms and shows a notable relationship with prognosis in patients with cancer.Never-theless,the function of FBXO22 in the context of colon cancer remains inade-quately elucidated.AIM To explore the role of FBXO22 in colon cancer by examining FBXO22 expression patterns and analyzing how the protein affects the prognosis in patients who have undergone surgery.METHODS Samples of cancerous and nearby normal tissues from patients with colon cancer were gathered,along with pertinent clinical data.Expression levels of the FBXO22 gene in both cancerous and paracancerous tissues were assessed through immu-nohistochemistry.The median H score served as a criterion for categorizing FBXO22 gene expression into high and low levels in cancerous tissues,and the relationship between these expression levels and various pathologic character-istics of patients,such as age,sex,and clinical stage,was analyzed.Colon cancer cell lines HCT116 and DLD-1 were used and divided into three groups:A blank control group,a negative control group,and a si-FBXO22 group.FBXO22 gene mRNA and protein expression were measured 24 hours post-transfection using real-time fluorescence quantitative polymerase chain reaction and western blotting.The proliferation capabilities of the cells in each group were assessed using the Cell Counting Kit-8 assay and 5-ethynyl-2’-deoxyuridine assay,while cellular migration and invasion abilities were evaluated using scratch healing and Transwell assays.Various online platforms,including the Timer Immune Estimation Resource,were used to analyze pan-cancer expression,promoter methylation levels,and mutation frequencies of the FBXO22 gene in colon cancer patients.Additionally,the correlation between FBXO22 gene expression,patient prognosis,immune cell infiltration,and the expression of immune molecules in the colon cancer microenvironment was investigated.The relationship between FBXO22 gene expression and chemotherapy resistance,along with the potential mechanisms of action of the FBXO22 gene,were analyzed using The Cancer Genome Atlas dataset and the Genomics of Drug Sensitivity in Cancer drug training set via R software.RESULTS Compared with normal colonic tissues,the FBXO22 gene was highly expressed in colon cancer tissues.Post-operative patients with colon cancer elevated FBXO22 reduced survival and exhibited resistance to various chemotherapeutic agents.FBXO22 expression suppresses the infiltration of anti-tumor immune cells.In vitro,FBXO22 knockdown inhibited the proliferation and migration of colon cancer cells.CONCLUSION The FBXO22 gene is a biomarker of poor prognosis in patients with colon cancer and has potential as a target for immunotherapy and overcoming chemotherapy resistance.
基金supported by the Youth support Program of Chinese General Hospital (Grand Number: 22QNFC044 to Niu S).
文摘Objective This study aimed to compare the upgrade rate and cancer detection rate between the 18F-DCFPyL PET/MRI-guided ultrasound fusion targeted biopsy(TB)and systematic biopsy in selected patients with suspected prostate cancer(the molecular imaging prostate-specific membrane antigen score of≥2 and multiparametric MRI Prostate Imaging Reporting and Data System score of≥4).Methods Eighty-seven selected biopsy-naive patients were randomized into two groups:TB(n=41)and systematic biopsy(control;n=46).Patients diagnosed with clinically significant prostate cancer proceeded to radical prostatectomy.The primary outcome was the pathological upgrade rate.Secondary outcomes,including the cancer detection rate,incidence of repeat biopsy,positive surgical margin,complications,and prostate-specific antigen level at 6 weeks postoperatively,were compared between the groups using the Pearson or Fisher's exact test,as appropriate.Results In the study,prostate cancer was ultimately detected in all patients.The TB group successfully identified all tumors,whereas five patients in the control group initially missed diagnosis.The pathological upgrade rates for the TB and control groups were 31.7%and 56.5%,respectively.Overall,the detection rate for clinically significant prostate cancer(the International Society of Urological Pathology grade of≥2)was significantly higher in the TB group(92.7%)compared with the control group(76.1%,p=0.035).However,no significant difference was found in the detection rate of all prostate cancer.Complications(Clavien–Dindo grade of≤2)occurred in both the TB group(n=11)and control group(n=13).No statistically significant difference was observed between the groups in terms of the positive surgical margin,complications,or 6-week postoperative prostate-specific antigen level.Conclusion The 18F-DCFPyL PET/MRI-guided ultrasound fusion TB alone was an efficient modality in diagnosing selected patients with prostate cancer.
